Advertisement

Topics

GSK, Innoviva: Trelegy Ellipta Gets CHMP Positive Opinion In Europe For COPD

03:01 EDT 15 Sep 2017 | FinanzNachrichten

LONDON (dpa-AFX) - GlaxoSmithKline Plc (GSK.L, GSK) and Innoviva, Inc. (INVA) announced Friday that Trelegy Ellipta once-daily single inhaler triple therapy received positive opinion from the Euro...

Original Article: GSK, Innoviva: Trelegy Ellipta Gets CHMP Positive Opinion In Europe For COPD

NEXT ARTICLE

More From BioPortfolio on "GSK, Innoviva: Trelegy Ellipta Gets CHMP Positive Opinion In Europe For COPD"

Quick Search
Advertisement
 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...